Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 247.53 +5.35 (+2.21%) Market Cap: 15.55 Bil Enterprise Value: 18.09 Bil PE Ratio: 0 PB Ratio: 3.42 GF Score: 73/100

Q1 2026 Jazz Pharmaceuticals PLC Earnings Call Transcript

May 05, 2026 / 08:30PM GMT
Release Date Price: $212.26 (+2.02%)
Operator

Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals 2026 first-quarter earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker for today, John Bluth, Head of Investor Relations. Please go ahead.

John Bluth
Jazz Pharmaceuticals PLC - Head of Investor Relations

Thank you and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its first-quarter 2026 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website along with the press release and quarterly report on Form 10-Q for the first quarter ended March 31, 2026. On the call today are Renee Gala, President and Chief Executive Officer; Sam Pearce, Chief Commercial Officer; Robbie Iannone, Global Head of R&D and Chief Medical Officer; and Phil Johnson, Chief Financial Officer.

On slide 2, I would like to remind you that today's webcast includes forward-looking statements, such as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot